Asparaginase erwinia chrysanthemi
What is Asparaginase erwinia chrysanthemi?[edit | edit source]
- Asparaginase erwinia chrysanthemi (RYLAZE) is an asparagine specific enzyme indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL).
What are the uses of this medicine?[edit | edit source]
This medicine is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 month or older who have developed hypersensitivity to E. coli-derived asparaginase.
How does this medicine work?[edit | edit source]
- An enzyme isolated from the bacterium Erwinia chrysanthemi (E. carotovora).
- Asparaginase erwinia chrysanthemi (recombinant)-rywn is an enzyme that catalyzes the conversion of the amino acid L-asparagine into aspartic acid and ammonia.
- The pharmacological effect of RYLAZE is based on the killing of leukemic cells due to depletion of plasma asparagine.
- Leukemic cells with low expression of asparagine synthetase have a reduced ability to synthesize asparagine, and therefore depend on an exogenous source of asparagine for survival.
Who Should Not Use this medicine ?[edit | edit source]
This medicine cannot be used in patients with:
- Serious hypersensitivity reactions to Erwinia asparaginase, including anaphylaxis
- Serious pancreatitis during previous asparaginase therapy
- Serious thrombosis during previous asparaginase therapy
- Serious hemorrhagic events during previous asparaginase therapy
Is this medicine FDA approved?[edit | edit source]
- It was approved for use in the United States in 2021.
How should this medicine be used?[edit | edit source]
Recommended Dosage
- When replacing a long-acting asparaginase product, the recommended dosage of RYLAZE is 25 mg/m2 administered intramuscularly every 48 hours.
Administration
- Visually inspect parenteral drug products for particulate matter, cloudiness, or discoloration prior to administration.
- If any of these are present, discard the vial.
- RYLAZE does not contain a preservative.
- Determine the dose, total volume of RYLAZE solution required, and the number of RYLAZE vials needed.
- More than one vial may be needed for a full dose.
- Withdraw the indicated injection volume of RYLAZE into the syringe for injection.
- Do not shake the vial.
- Limit the volume of RYLAZE at a single injection site to 2 mL.
- If the volume to be administered is greater than 2 mL, divide the doses equally into multiple syringes, one for each injection site.
- Discard the remaining unused RYLAZE in the single-dose vial.
- Administer RYLAZE by intramuscular injection within 4 hours after drawing the dose into the syringe(s).
- Rotate injection sites.
- Do not inject RYLAZE into scar tissue or areas that are reddened, inflamed, or swollen.
- If needed, store the syringe(s) at room temperature (15°C to 25°C [59°F to 77°F]) or refrigerated at 2°C to 8°C (36°F to 46°F) for up to 4 hours. The syringe does not need to be protected from light during storage.
What are the dosage forms and brand names of this medicine?[edit | edit source]
This medicine is available in fallowing doasage form:
- As Injection: 10 mg/0.5 mL solution in a single-dose vial.
This medicine is available in fallowing brand namesː
- RYLAZE
What side effects can this medication cause?[edit | edit source]
The most common side effects of this medicine include:
- abnormal liver test
- nausea
- musculoskeletal pain
- fatigue
- infection
- headache
- pyrexia
- drug hypersensitivity
- febrile neutropenia
- decreased appetite
- stomatitis
- bleeding
- hyperglycemia
What special precautions should I follow?[edit | edit source]
- Monitor for signs or symptoms of hypersensitivity. Discontinue RYLAZE for serious reaction.
- Monitor for symptoms of pancreatitis. Discontinue if pancreatitis occurs.
- Discontinue RYLAZE for severe or life-threatening thrombosis. Provide anticoagulation therapy as indicated.
- Discontinue RYLAZE for severe or life-threatening hemorrhage.
- This medicine can cause hepatotoxicity. Discontinue RYLAZE for grade 4 increases of bilirubin.
What to do in case of emergency/overdose?[edit | edit source]
- In case of overdose, call the poison control helpline of your country. In the United States, call 1-800-222-1222.
- Overdose related information is also available online at poisonhelp.org/help.
- In the event that the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services. In the United States, call 911.
Can this medicine be used in pregnancy?[edit | edit source]
- Based on findings from animal reproduction studies, RYLAZE can cause fetal harm when administered to a pregnant woman.
- There are no available data on RYLAZE use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.
Can this medicine be used in children?[edit | edit source]
- The safety and effectiveness of RYLAZE in the treatment of ALL and LBL have been established in pediatric patients 1 month to < 17 years who have developed hypersensitivity to a long-acting E. coli-derived asparaginase.
- The safety and effectiveness of RYLAZE have not been established in pediatric patients younger than 1 month of age.
What are the active and inactive ingredients in this medicine?[edit | edit source]
Active ingredient:
- ASPARAGINASE
Inactive ingredients:
- TREHALOSE DIHYDRATE
- SODIUM CHLORIDE
- SODIUM PHOSPHATE, DIBASIC, ANHYDROUS
- SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE
- POLYSORBATE 80
Who manufactures and distributes this medicine?[edit | edit source]
Packager: Jazz Pharmaceuticals, Inc.
What should I know about storage and disposal of this medication?[edit | edit source]
- Store RYLAZE vials refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light.
- Do not shake or freeze.
Asparaginase erwinia chrysanthemi Resources | |
---|---|
|
This article is a stub. You can help WikiMD by registering to expand it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Deepika vegiraju